AdaptHealth Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of AdaptHealth Corp.'s annual meeting of stockholders held on June 18, 2025. The meeting was conducted via live audio webcast. As of the record date (April 24, 2025), there were 126,498,289 shares of common stock present or represented by proxy, representing 93.32% of the voting power, which constituted a quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on three proposals. The results are as follows:
- Election of Directors: All six nominees were elected for a one-year term.
- Dr. Susan Weaver received the highest support with 101,119,825 votes "For".
- Brad Coppens received the lowest support among nominees with 71,068,723 votes "For".
- Significant "Withheld" votes were recorded for all nominees, ranging from approximately 11 million to 41 million shares.
- Ratification of Independent Auditor: Stockholders ratified the appointment of KPMG LLP for the fiscal year ending December 31, 2025.
- For: 124,299,342
- Against: 2,086,471
- Abstain: 112,476
- Executive Compensation (Say-on-Pay): Stockholders approved the non-binding advisory vote on executive compensation.
- For: 105,733,612
- Against: 6,409,613
- Abstain: 40,368
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific reasons for the high volume of "Withheld" votes on director elections, particularly for Brad Coppens and Terence Connors.
- Confirm the tenure and background of the newly elected directors serving until the 2026 annual meeting.
- Review the definitive proxy statement filed on April 30, 2025, for detailed context on the executive compensation package approved by shareholders.
- Monitor future filings for the company's financial performance, as this 8-K contains no financial data.